Capacity Expansion
OneSource Receives Karnataka Government Approval for Unit II Expansion Incentives
NSE
onesource
BSE
544292
OneSource Specialty Pharma Limited announced that the Government of Karnataka has granted in-principle approval for incentives and concessions related to the expansion of its Unit II manufacturing facility under the Karnataka Industrial Policy (KIP) 2025–30.
PRICE-SENSITIVE TRIGGER
Event: Government approval for Unit II expansion project incentives under Karnataka Industrial Policy.
Type: Capacity Expansion
Impact: Positive
Immediate Effect: The approval supports OneSource’s manufacturing expansion plans and strengthens its long-term growth strategy for servicing global pharmaceutical partners.
Key Metrics:
- In-principle approval granted under:
- Karnataka Industrial Policy (KIP) 2025–30
- Expansion relates to:
- Unit II manufacturing facility
- Government Order No.:
- CI 120 SPI 2026
- Government order dated:
- May 12, 2026
- Approval received by company on:
- May 15, 2026
Highlight:
- The proposed Unit II expansion is positioned as a major growth initiative aimed at enhancing manufacturing capacities for global pharmaceutical clients.
What Happened ?
OneSource Specialty Pharma informed stock exchanges that the Government of Karnataka has accorded in-principle approval for incentives and concessions tied to the company’s Unit II expansion project.
The approval was granted following consideration by the 67th State High Level Clearance Committee (SHLCC) meeting held on April 13, 2026.
The project pertains to the expansion of the company’s Unit II facility located at the KIADB Industrial Area in Bengaluru Rural District.
Key Details
Expansion Project Details:
- Expansion planned at:
- Unit II facility
- Obadenahalli, KIADB Industrial Area
- Doddaballapur Taluk, Bengaluru Rural District
Government Approval:
- Approval granted under Karnataka Industrial Policy 2025–30
- Incentives and concessions approved in principle
- SHLCC reviewed the proposal during its 67th meeting
Strategic Importance:
- Unit II identified as a flagship manufacturing facility
- Expansion expected to significantly enhance production capacity
- Supports servicing of global pharmaceutical partners
- Aligns with long-term growth and scaling strategy
Risk Analysis
Key Risks:
- Project execution and commissioning risks
- Dependence on future regulatory and operational clearances
- Potential capex escalation during expansion
- Demand fluctuations from global pharma clients
Worst Case Scenario:
- If project execution faces delays or expected global demand does not materialize, return on expansion investments could remain below expectations.
Risk Level: Medium
Company Commentary
- The company stated that Unit II is a flagship manufacturing facility
- Management described the expansion as a significant step in its growth strategy
- OneSource emphasized the project’s role in enhancing manufacturing capabilities for global customers
- The company confirmed receipt of the Karnataka Government order on May 15, 2026
Official Exchange Filing: OneSource Specialty Pharma Limited